How many carbonic anhydrase inhibition mechanisms exist?

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 31, Issue 3, 2016, Pages 345-360

  Supuran, Claudiu T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Anchoring to zinc coordinated water; carbonic anhydrase; inhibition mechanism; inhibitors; occlusion of the active site entrance; out of the active site binding; zinc binder

Indexed keywords

ACETAZOLAMIDE; BRINZOLAMIDE; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE INHIBITOR; CARBOXYLIC ACID DERIVATIVE; CELECOXIB; COUMARIN; DICLOFENAMIDE; DORZOLAMIDE; ETHOXZOLAMIDE; FUROSEMIDE; GENTISIC ACID; HYDROXIDE; PHENOL; PROBENECID; RESORCINOL; SACCHARIN; SULFONAMIDE; SULPIRIDE; SULTIAME; TOPIRAMATE; WATER; ZINC ION; ZONISAMIDE;

DRUG BINDING SITE; DRUG DESIGN; ENZYME ACTIVE SITE; ENZYME INHIBITION; PRIORITY JOURNAL; REVIEW; SCIENTIFIC MISCONDUCT; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; METABOLISM; MOLECULAR MODEL;

ANIMALS; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE;

EID: 84961206327     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2015.1122001     Document Type: Review

References (174)

1. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008; 7: 168-81
2. Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011; 10: 767-77
3. Capasso C, Supuran CT. An overview of the alpha-, beta-and gamma-carbonic anhydrases from Bacteria: can bacterial carbonic anhydrases shed new light on evolution of bacteria? J Enzyme Inhib Med Chem 2015; 30: 325-32
4. Supuran CT, Capasso C. The η-class carbonic anhydrases as drug targets for antimalarial agents. Expert Opin Ther Targets 2015; 19: 551-63
5. Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2012; 27: 759-72
6. Supuran CT. Carbonic anhydrase inhibitors. Bioorg Med Chem Lett 2010; 20: 3467-74
7. Pastorekova S, Parkkila S, Pastorek J, Supuran CT. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem 2004; 19: 199-229
8. Supuran CT. Carbonic anhydrase inhibitors and activators for novel therapeutic applications. Future Med Chem 2011; 3: 1165-80
9. Supuran CT. Bacterial carbonic anhydrases as drug targets: toward novel antibiotics? Front Pharmacol 2011; 2: 34
10. Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003; 23: 146-89
11. Del Prete S, Vullo D, De Luca V, et al. Biochemical characterization of the δ-carbonic anhydrase from the marine diatom Thalassiosira weissflogii, TweCA. J Enzyme Inhib Med Chem 2014; 29: 906-11
12. De Simone G, Supuran CT. (In)organic anions as carbonic anhydrase inhibitors. J Inorg Biochem 2012; 111: 117-29
13. Del Prete S, Vullo D, De Luca V, et al. Biochemical characterization of recombinant β-carbonic anhydrase (PgiCAb) identified in the genome of the oral pathogenic bacterium Porphyromonas gingivalis. J Enzyme Inhib Med Chem 2015; 30: 366-70
14. Supuran CT. Carbonic anhydrase inhibitors: an editorial. Expert Opin Ther Pat 2013; 23: 677-9
15. Supuran CT. Carbonic anhydrases: from biomedical applications of the inhibitors and activators to biotechnological use for CO(2) capture. J Enzyme Inhib Med Chem 2013; 28: 229-30
16. Capasso C, Supuran CT. Anti-infective carbonic anhydrase inhibitors: a patent and literature review. Expert Opin Ther Pat 2013; 23: 693-704
17. Capasso C, Supuran CT. Sulfa and trimethoprim-like drugs-antimetabolites acting as carbonic anhydrase, dihydropteroate synthase and dihydrofolate reductase inhibitors. J Enzyme Inhib Med Chem 2014; 29: 379-87
18. Supuran CT, Scozzafava A. Carbonic anhydrases as targets for medicinal chemistry. Bioorg Med Chem 2007; 15: 4336-50
19. Lou Y, McDonald PC, Oloumi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 2011; 71: 3364-76
20. Zimmerman S, Innocenti A, Casini A, et al. Carbonic anhydrase inhibitors. Inhibition of the prokaryotic beta and gamma-class enzymes from Archaea with sulfonamides. Bioorg Med Chem Lett 2004; 14: 6001-6
21. Alterio V, Di Fiore A, DAmbrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev 2012; 112: 4421-68
22. Temperini C, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. X-Ray crystal studies of the carbonic anhydrase II-trithiocarbonate adduct-an inhibitor mimicking the sulfonamide and urea binding to the enzyme. Bioorg Med Chem Lett 2010; 20: 474-8
23. Briganti F, Mangani S, Orioli P, et al. Carbonic anhydrase activators: X-ray crystallographic and spectroscopic investigations for the interaction of isozymes I and II with histamine. Biochemistry 1997; 36: 10384-92
24. Temperini C, Scozzafava A, Vullo D, Supuran CT. Carbonic anhydrase activators. Activation of isozymes I, II, IV, VA, VII and XIV with L-and D-histidine and crystallographic analysis of their adducts with isoform II: engineering proton transfer processes within the active site of an enzyme. Chemistry 2006; 12: 7057-66
25. Vullo D, De Luca V, Del Prete S, et al. Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune. Bioorg Med Chem 2015; 23: 1728-34
26. Schlicker C, Hall RA, Vullo D, et al. Structure and inhibition of the CO 2-sensing carbonic anhydrase Can2 from the pathogenic fungus Cryptococcus neoformans. J Mol Biol 2009; 385: 1207-20
27. Pacchiano F, Carta F, Vullo D, et al. Inhibition of β-carbonic anhydrases with ureido-substituted benzenesulfonamides. Bioorg Med Chem Lett 2010; 20: 102-5
28. Carta F, Aggarwal M, Maresca A, et al. Dithiocarbamates strongly inhibit carbonic anhydrases and show antiglaucoma action in vivo. J Med Chem 2012; 55: 1721-30
29. Monti SM, Maresca A, Viparelli F, et al. Dithiocarbamates strongly inhibit the beta-class fungal carbonic anhydrases from Cryptococcus neoformans, Candida albicans and Candida glabrata. Bioorg Med Chem Lett 2012; 22: 859-62
30. Maresca A, Carta F, Vullo D, Supuran CT. Dithiocarbamates strongly inhibit the β-class carbonic anhydrases from Mycobacterium tuberculosis. J Enzyme Inhib Med Chem 2013; 28: 407-11
31. Carta F, Innocenti A, Hall RA, et al. Carbonic anhydrase inhibitors. Inhibition of the β-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with branched aliphatic-/aromatic carboxylates and their derivatives. Bioorg Med Chem Lett 2011; 21: 2521-6
32. Nishimori I, Onishi S, Takeuchi H, Supuran CT. The alpha and beta classes carbonic anhydrases from Helicobacter pylori as novel drug targets. Curr Pharm Des 2008; 14: 622-30
33. Minakuchi T, Nishimori I, Vullo D, et al. Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate. J Med Chem 2009; 52: 2226-32
34. Nishimori I, Minakuchi T, Vullo D, et al. Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new β-carbonic anhydrase from Mycobacterium tuberculosis. J Med Chem 2009; 52: 3116-20
35. Güzel Ö, Maresca A, Scozzafava A, et al. Discovery of low nanomolar and subnanomolar inhibitors of the mycobacterial beta-carbonic anhydrases Rv1284 and Rv3273. J Med Chem 2009; 52: 4063-7
36. Carta F, Maresca A, Suarez Covarrubias A, et al. Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c. Bioorg Med Chem Lett 2009; 19: 6649-54
37. Nishimori I, Minakuchi T, Maresca A, et al. The β-carbonic anhydrases from Mycobacterium tuberculosis as drug targets. Curr Pharm Des 2010; 16: 3300-9
38. Winum JY, Kohler S, Supuran CT. Brucella carbonic anhydrases: new targets for designing anti-infective agents. Curr Pharm Des 2010; 16: 3310-16
39. Vullo D, Nishimori I, Minakuchi T, et al. Inhibition studies with anions and small molecules of two novel β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium. Bioorg Med Chem Lett 2011; 21: 3591-5
40. Maresca A, Vullo D, Scozzafava A, Supuran CT. Inhibition of the alpha-and beta-carbonic anhydrases from the gastric pathogen Helycobacter pylori with anions. J Enzyme Inhib Med Chem 2013; 28: 388-91
41. Maresca A, Vullo D, Scozzafava A, et al. Inhibition of the beta-class carbonic anhydrases from Mycobacterium tuberculosis with carboxylic acids. J Enzyme Inhib Med Chem 2013; 28: 392-6
42. Vullo D, Nishimori I, Scozzafava A, et al. Inhibition studies of a beta-carbonic anhydrase from Brucella suis with a series of water soluble glycosyl sulfanilamides. Bioorg Med Chem Lett 2010; 20: 2178-82
43. Nishimori I, Minakuchi T, Kohsaki T, et al. Carbonic anhydrase inhibitors: the beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors. Bioorg Med Chem Lett 2007; 17: 3585-94
44. Weber A, Casini A, Heine A, et al. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem 2004; 47: 550-7
45. Di Fiore A, Pedone C, DAmbrosio K, et al. Carbonic anhydrase inhibitors: valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related, cyclooxygenase II "selective" inhibitor celecoxib. Bioorg Med Chem Lett 2006; 16: 437-42
46. Köhler K, Hillebrecht A, Schulze Wischeler J, et al. Saccharin inhibits carbonic anhydrases: possible explanation for its unpleasant metallic aftertaste. Angew Chem Int Ed Engl 2007; 46: 7697-9
47. Casini A, Scozzafava A, Mincione F, et al. Carbonic anhydrase inhibitors: water-soluble 4-sulfamoylphenylthioureas as topical intraocular pressure-lowering agents with long-lasting effects. J Med Chem 2000; 43: 4884-92
48. Scozzafava A, Menabuoni L, Mincione F, Supuran CT. Carbonic anhydrase inhibitors. A general approach for the preparation of water-soluble sulfonamides incorporating polyamino-polycarboxylate tails and of their metal complexes possessing long-lasting, topical intraocular pressure-lowering properties. J MedChem 2002; 45: 1466-76
49. Fabrizi F, Mincione F, Somma T, et al. A new approach to antiglaucoma drugs: carbonic anhydrase inhibitors with or without NO donating moieties. Mechanism of action and preliminary pharmacology. J Enzyme Inhib Med Chem 2012; 27: 138-47
50. Ebbesen P, Pettersen EO, Gorr TA, et al. Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies. J Enzyme Inhib Med Chem 2009; 24: 1-39
51. Švastová E, Hulíková A, Rafajová M, et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 2004; 577: 439-45
52. Dubois L, Lieuwes NG, Maresca A, et al. Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. Radiother Oncol 2009; 92: 423-8
53. Ahlskog JKJ, Dumelin CE, Trüssel S, et al. In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives. Bioorg Med Chem Lett 2009; 19: 4851-6
54. Pacchiano F, Carta F, McDonald PC, et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem 2011; 54: 1896-902
55. Mincione F, Scozzafava A, Supuran CT. The development of topically acting carbonic anhydrase inhibitors as anti-glaucoma agents. Curr Top Med Chem 2007; 7: 849-54
56. Carta F, Supuran CT, Scozzafava A. Novel therapies for glaucoma: a patent review 2007-2011. Expert Opin Ther Pat 2012; 22: 79-88
57. Steele RM, Batugo MR, Benedini F, et al. Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma. Bioorg Med Chem Lett 2009; 19: 6565-70
58. Mincione F, Benedini F, Biondi S, et al. Synthesis and crystallographic analysis of new sulfonamides incorporating NO-donating moieties with potent antiglaucoma action. Bioorg Med Chem Lett 2011; 21: 3216-21
59. Alterio V, Vitale RM, Monti SM, et al. Carbonic anhydrase inhibitors: X-ray and molecular modeling study for the interaction of a fluorescent antitumor sulfonamide with isozyme II and IX. J Am Chem Soc 2006; 128: 8329-35
60. Alterio V, De Simone G, Monti SM, et al. Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides-Solution and crystallographic studies. Bioorg Med Chem Lett 2007; 17: 4201-7
61. Wagner J, Avvaru BS, Robbins AH, et al. Coumarinyl-substituted sulfonamides strongly inhibit several human carbonic anhydrase isoforms: solution and crystallographic investigations. Bioorg Med Chem 2010; 18: 4873-8
62. Biswas S, Aggarwal M, Guzel O, et al. Conformational variability of different sulfonamide inhibitors with thienyl-acetamido moieties attributes to differential binding in the active site of cytosolic human carbonic anhydrase isoforms. Bioorg Med Chem 2011; 19: 3732-8
63. Pacchiano F, Aggarwal M, Avvaru BS, et al. Selective hydrophobic pocket binding observed within the carbonic anhydrase II active site accommodate different 4-substituted-ureido-benzenesulfonamides and correlate to inhibitor potency. Chem Commun (Camb) 2010; 46: 8371-3
64. Carta F, Garaj V, Maresca A, et al. Sulfonamides incorporating 1,3,5-triazine moieties selectively and potently inhibit carbonic anhydrase transmembrane isoforms IX, XII and XIV over cytosolic isoforms I and II: solution and X-ray crystallographic studies. Bioorg Med Chem 2011; 19: 3105-19
65. Hen N, Bialer M, Yagen B, et al. Anticonvulsant 4-aminobenzenesulfonamide derivatives with branched-alkylamide moieties: X-ray crystallography and inhibition studies of human carbonic anhydrase isoforms I, II, VII and XIV. J Med Chem 2011; 54: 3977-81
66. Kolayli S, Karahalil F, Sahin H, et al. Characterization and inhibition studies of an α-carbonic anhydrase from the endangered sturgeon species Acipenser gueldenstaedti. J Enzyme Inhib Med Chem 2011; 26: 895-900
67. Güzel Ö, Innocenti A, Scozzafava A, et al. Carbonic anhydrase inhibitors. Phenacetyl-, pyridylacetyl-and thienylacetyl-substituted aromatic sulfonamides act as potent and selective isoform VII inhibitors. Bioorg Med Chem Lett 2009; 19: 3170-3
68. Güzel Ö, Innocenti A, Scozzafava A, et al. Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl-, pyridylacetyl-and thienylacetyl-tails act as potent inhibitors of human mitochondrial isoforms VA and VB. Bioorg Med Chem 2009; 17: 4894-9
69. Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Arylsulfonylureido and arylureido-substituted aromatic and heterocyclic sulfonamides: towards selective inhibitors of carbonic anhydrase isozyme I. J Enzyme Inhib 1999; 14: 343-63
70. Garaj V, Puccetti L, Fasolis G, et al. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II and IX with sulfonamides incorporating 1,2,4-triazine moieties. Bioorg Med Chem Lett 2004; 14: 5427-33
71. Garaj V, Puccetti L, Fasolis G, et al. Carbonic anhydrase inhibitors. Novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II and IX. Bioorg Med Chem Lett 2005; 15: 3102-8
72. McDonald PC, Winum JY, Supuran CT, Dedhar S. Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget 2012; 3: 84-97
73. 2): a patent review 2008-2012. Expert Opin Ther Pat 2012; 22: 747-58
74. Masini E, Carta F, Scozzafava A, Supuran CT. Antiglaucoma carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat 2013; 23: 705-16
75. Monti SM, Supuran CT, De Simone G. Anticancer carbonic anhydrase inhibitors: a patent review (2008-2013). Expert Opin Ther Pat 2013; 23: 737-49
76. Carta F, Supuran CT. Diuretics with carbonic anhydrase inhibitory action: a patent and literature review (2005-2013). Expert Opin Ther Pat 2013; 23: 681-91
77. Supuran CT. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs 2012; 17: 11-15
78. Scozzafava A, Supuran CT, Carta F. Antiobesity carbonic anhydrase inhibitors: a literature and patent review. Expert Opin Ther Pat 2013; 23: 725-35
79. Supuran CT. The safety and clinical efficacy of acetazolamide for the treatment of idiopathic intracranial hypertension. Expert Rev Neurother 2015; 15: 851-6
80. De Simone G, Alterio V, Supuran CT. Exploiting the hydrophobic and hydrophilic binding sites for designing carbonic anhydrase inhibitors. Expert Opin Drug Discov 2013; 8: 793-810
81. Scozzafava A, Menabuoni L, Mincione F, et al. Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring? J Med Chem 1999; 42: 2641-50
82. Borras J, Scozzafava A, Menabuoni L, et al. Carbonic anhydrase inhibitors. Part 73. Synthesis of water-soluble, topically effective intraocular pressure lowering aromatic/heterocyclic sulfonamides containing 8-quinoline-sulfonyl moieties: is the tail more important than the ring? Bioorg Med Chem 1999; 7: 2397-406
83. Carta F, Aggarwal M, Maresca A, et al. Dithiocarbamates: a new class of carbonic anhydrase inhibitors. Crystallographic and kinetic investigations. Chem Commun (Camb) 2012; 48: 1868-70
84. Carta F, Akdemir A, Scozzafava A, et al. Xanthates and trithiocarbonates strongly inhibit carbonic anhydrases and show antiglaucoma effects in vivo. J Med Chem 2013; 56: 4691-700
85. Mori M, Cau Y, Vignaroli G, et al. Hit recycling: discovery of a potent carbonic anhydrase inhibitor by in silico target fishing. ACS Chem Biol 2015; 10: 1964-9
86. Innocenti A, Vullo D, Scozzafava A, et al. Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V and IX with carboxylates. Bioorg Med Chem Lett 2005; 15: 573-8
87. Rusconi S, Innocenti A, Vullo D, et al. Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V and IX with phosphates, carbamoyl phosphate and the phosphonate antiviral drug foscarnet. Bioorg Med Chem Lett 2004; 14: 5763-7
88. Temperini C, Innocenti A, Guerri A, et al. Phosph(on)ate as a zinc binding group in metalloenzyme inhibitors: X-ray crystal structure of the antiviral drug foscarnet complexed to human carbonic anhydrase I. Bioorg Med Chem Lett 2007; 17: 2210-15
89. Tauro M, Loiodice F, Ceruso M, et al. Dual carbonic anhydrase/matrix metalloproteinase inhibitors incorporating bisphosphonic acid moieties targeting bone tumors. Bioorg Med Chem Lett 2014; 24: 2617-20
90. Tauro M, Loiodice F, Ceruso M, et al. Arylamino bisphosphonates: potent and selective inhibitors of the tumor-associated carbonic anhydrase XII. Bioorg Med Chem Lett 2014; 24: 1941-3
91. Reich R, Hoffman A, Veerendhar A, et al. Carbamoylphosphonates control tumor cell proliferation and dissemination by simultaneously inhibiting carbonic anhydrase IX and matrix metalloproteinase-2. Toward nontoxic chemotherapy targeting tumor microenvironment. J Med Chem 2012; 55: 7875-82
92. Reich R, Hoffman A, Suresh RR, et al. Carbamoylphosphonates inhibit autotaxin and metastasis formation in vivo. J Enzyme Inhib Med Chem 2015; 30: 767-72
93. Scozzafava A, Supuran CT. Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. J Med Chem 2000; 43: 3677-87
94. Santos MA, Marques S, Gil M, et al. Protease inhibitors: synthesis of bacterial collagenase and matrix metalloproteinase inhibitors incorporating succinylhydroxamate and iminodiacetic acid hydroxamate moieties. J Enzyme Inhib Med Chem 2003; 18: 233-42
95. Scozzafava A, Supuran CT. Hydroxyurea is a carbonic anhydrase inhibitor. Bioorg Med Chem 2003; 11: 2241-6
96. Nuti E, Orlandini E, Nencetti S, et al. Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates. Bioorg Med Chem 2007; 15: 2298-311
97. Santos MA, Marques S, Vullo D, et al. Carbonic anhydrase inhibitors. Inhibition of cytosolic/tumor-associated isoforms I, II and IX with iminodiacetic carboxylates/hydroxamates also incorporating benzenesulfonamide moieties. Bioorg Med Chem Lett 2007; 17: 1538-43
98. Marques SM, Nuti E, Rossello A, et al. Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates. J Med Chem 2008; 51: 7968-79
99. Di Fiore A, Maresca A, Supuran CT, De Simone G. Hydroxamate represents a versatile zinc binding group for the development of new carbonic anhydrase inhibitors. Chem Commun (Camb) 2012; 48: 8838-40
100. Supuran CT. Hydroxamates as carbonic anhydrase inhibitors. In: Gupta SP., ed. Hydroxamic acids: a unique family of chemicals with multiple biological activities. Heidelberg: Springer Verlag; 2013: 55-69
101. Langella E, DAmbrosio K, DAscenzio M, et al. A combined crystallographic and theoretical study explains the capability of carboxylic acids to adopt multiple binding modes within carbonic anhydrase active site. Chemistry 2015; in press.
102. Bozdag M, Carta F, Vullo D, et al. Synthesis of a new series of dithiocarbamates with effective human carbonic anhydrase inhibitory activity and antiglaucoma action. Bioorg Med Chem 2015; 23: 2368-76
103. Nair SK, Ludwig PA, Christianson DW. Two-site binding of phenol in the active site of human carbonic anhydrase II: structural implications for substrate association. J Am Chem Soc 1994; 116: 3659-60
104. Carta F, Temperini C, Innocenti A, et al. Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem 2010; 53: 5511-22
105. Innocenti A, Vullo D, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Interactions of phenols with the 12 catalytically active mammalian isoforms (CA I-XIV). Bioorg Med Chem Lett 2008; 18: 1583-7
106. Innocenti A, Vullo D, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem 2008; 16: 7424-8
107. Bayram E, Senturk M, Kufrevioglu OI, Supuran CT. In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II. Bioorg Med Chem 2008; 16: 9101-5
108. Şentürk M, Gülçin I, Daştan A, et al. Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols. Bioorg Med Chem 2009; 17: 3207-11
109. Innocenti A, Öztürk Sarikaya SB, Gülçin I, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem 2010; 18: 2159-64
110. Davis RA, Innocenti A, Poulsen SA, Supuran CT. Carbonic anhydrase inhibitors. Identification of selective inhibitors of the human mitochondrial isozymes VA and VB over the cytosolic isozymes I and II from a natural product-based phenolic library. Bioorg Med Chem 2010; 18: 14-18
111. Davis RA, Hofmann A, Osman A, et al. Natural product-based phenols as novel probes for mycobacterial and fungal carbonic anhydrases. J Med Chem 2011; 54: 1682-92
112. Carta F, Vullo D, Maresca A, et al. Mono-/dihydroxybenzoic acid esters and phenol pyridinium derivatives as inhibitors of the mammalian carbonic anhydrase isoforms I, II, VII, IX, XII and XIV. Bioorg Med Chem 2013; 21: 1564-9
113. Martin DP, Cohen SM. Nucleophile recognition as an alternative inhibition mode for benzoic acid based carbonic anhydrase inhibitors. Chem Commun (Camb) 2012; 48: 5259-61
114. Tars K, Vullo D, Kazaks A, et al. Sulfocoumarins (1,2-benzoxathiine-2,2-dioxides): a class of potent and isoform-selective inhibitors of tumor-associated carbonic anhydrases. J Med Chem 2013; 56: 293-300
115. Buchieri MV, Riafrecha LE, Rodríguez OM, et al. Inhibition of the β-carbonic anhydrases from Mycobacterium tuberculosis with C-cinnamoyl glycosides: identification of the first inhibitor with anti-mycobacterial activity. Bioorg Med Chem Lett 2013; 23: 740-3
116. Riafrecha LE, Rodríguez OM, Vullo D, et al. Synthesis of C-cinnamoyl glycosides and their inhibitory activity against mammalian carbonic anhydrases. Bioorg Med Chem 2013; 21: 1489-94
117. Ekinci D, Karagoz L, Ekinci D, et al. Carbonic anhydrase inhibitors: in vitro inhibition of α isoforms (hCA I, hCA II, bCA III, hCA IV) by flavonoids. J Enzyme Inhib Med Chem 2013; 28: 283-8
118. Sahin H, Can Z, Yildiz O, et al. Inhibition of carbonic anhydrase isozymes I and II with natural products extracted from plants, mushrooms and honey. J Enzyme Inhib Med Chem 2012; 27: 395-402
119. Supuran CT. Carbonic anhydrase inhibition with natural products: novel chemotypes and inhibition mechanisms. Mol Divers 2011; 15: 305-16
120. Karioti A, Ceruso M, Carta F, et al. New natural product carbonic anhydrase inhibitors incorporating phenol moieties. Bioorg Med Chem 2015; 23: 7219-25
121. Maresca A, Akyuz G, Osman SM, et al. Inhibition of mammalian carbonic anhydrase isoforms I-XIV with a series of phenolic acid esters. Bioorg Med Chem 2015; 23: 7181-8
122. Ferraroni M, Carta F, Scozzafava A, Supuran CT. Thioxocoumarins inhibit carbonic anhydrases through a different mechanism compared to coumarins. J Med Chem 2015; submitted
123. Huang S, Hainzl T, Grundström C, et al. Structural studies of β-carbonic anhydrase from the green alga Coccomyxa: inhibitor complexes with anions and acetazolamide. PLoS One 2011; 6: e28458
124. Maresca A, Temperini C, Vu H, et al. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc 2009; 131: 3057-62
125. Maresca A, Temperini C, Pochet L, et al. Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem 2010; 53: 335-44
126. Temperini C, Innocenti A, Scozzafava A, et al. The coumarin-binding site in carbonic anhydrase accommodates structurally diverse inhibitors: the antiepileptic lacosamide as an example and lead molecule for novel classes of carbonic anhydrase inhibitors. J Med Chem 2010; 53: 850-4
127. Touisni N, Maresca A, McDonald PC, et al. Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors. J Med Chem 2011; 54: 8271-7
128. Bonneau A, Maresca A, Winum JY, Supuran CT. Metronidazole-coumarin conjugates and 3-cyano-7-hydroxy-coumarin act as isoform-selective carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2013; 28: 397-401
129. Sharma A, Tiwari M, Supuran CT. Novel coumarins and benzocoumarins acting as isoform-selective inhibitors against the tumor-associated carbonic anhydrase IX. J Enzyme Inhib Med Chem 2014; 29: 292-6
130. Maresca A, Supuran CT. Coumarins incorporating hydroxy-and chloro-moieties selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II. Bioorg Med Chem Lett 2010; 20: 4511-4
131. Maresca A, Scozzafava A, Supuran CT. 78-Disubstituted-but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II in the low nanomolar/subnanomolar range. Bioorg Med Chem Lett 2010; 20: 7255-8
132. Carta F, Maresca A, Scozzafava A, et al. 5-and 6-membered (thio)lactones are prodrug type carbonic anhydrase inhibitors. Bioorg Med Chem Lett 2012; 22: 267-70
133. Isik S, Vullo D, Bozdag M, et al. 7-Amino-3,4-dihydro-1H-quinoline-2-one, a compound similar to the substituted coumarins, inhibits α-carbonic anhydrases without hydrolysis of the lactam ring. J Enzyme Inhib Med Chem 2015; 30: 773-7
134. Tanc M, Carta F, Bozdag M, et al. 7-Substituted-sulfocoumarins are isoform-selective, potent carbonic anhydrase II inhibitors. Bioorg Med Chem 2013; 15: 4502-10
135. Grandane A, Tanc M, Zalubovskis R, et al. 6-Triazolylsubstituted sulfocoumarins are potent, selective inhibitors of the tumor-associated carbonic anhydrases IX and XII. Bioorg Med Chem Lett 2014; 24: 1256-60
136. Grandane A, Tanc M, Zalubovskis R, et al. Synthesis of 6-tetrazolyl-substituted sulfocoumarins acting as highly potent and selective inhibitors of the tumor-associated carbonic anhydrase isoforms IX and XII. Bioorg Med Chem 2014; 22: 1522-8
137. Grandane A, Tanc M, Di Cesare Mannelli L, et al. 6-Substituted sulfocoumarins are selective carbonic anhdydrase IX and XII inhibitors with significant cytotoxicity against colorectal cancer cells. J Med Chem 2015; 58: 3975-83
138. Tanc M, Carta F, Scozzafava A, et al. 6-Substituted 1,2-benzoxathiine-2,2-dioxides are isoform-selective inhibitors of human carbonic anhydrases IX, XII and VA. Org Biomol Chem 2015; 13: 77-80
139. DAmbrosio K, Carradori S, Monti SM, et al. Out of the active site binding pocket for carbonic anhydrase inhibitors. Chem Commun 2015; 51: 302-5
140. Scozzafava A, Carta F, Supuran CT. Secondary and tertiary sulfonamides: a patent review (2008-2012). Expert Opin Ther Pat 2013; 23: 203-13
141. Alp C, Ozsoy S, Alp NA, et al. Sulfapyridine-like benzenesulfonamide derivatives as inhibitors of carbonic anhydrase isoenzymes I, II and VI. J Enzyme Inhib Med Chem 2012; 27: 818-24
142. Ekinci D, Fidan I, Durdagi S, et al. Kinetic and in silico analysis of thiazolidin-based inhibitors of α-carbonic anhydrase isoenzymes. J Enzyme Inhib Med Chem 2013; 28: 370-4
143. Abdel-Aziz AA, El-Azab AS, Ekinci D, et al. Investigation of arenesulfonyl-2-imidazolidinones as potent carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2015; 30: 81-4
144. Arslan M, Şentürk M, Fidan I, et al. Synthesis of 3,4-dihydroxypyrrolidine-2,5-dione and 3,5-dihydroxybenzoic acid derivatives and evaluation of the carbonic anhydrase I and II inhibition. J Enzyme Inhib Med Chem 2015; 30: 896-900
145. Liu F, Martin-Mingot A, Lecornué F, et al. Carbonic anhydrases inhibitory effects of new benzenesulfonamides synthesized by using superacid chemistry. J Enzyme Inhib Med Chem 2012; 27: 886-91
146. Compain G, Martin-Mingot A, Maresca A, et al. Superacid synthesis of halogen containing N-substituted-4-aminobenzene sulfonamides: new selective tumor-associated carbonic anhydrase inhibitors. Bioorg Med Chem 2013; 21: 1555-63
147. Métayer B, Mingot A, Vullo D, et al. New superacid synthesized (fluorinated) tertiary benzenesulfonamides acting as selective hCA IX inhibitors: toward a new mode of carbonic anhydrase inhibition by sulfonamides. Chem Commun (Camb) 2013; 49: 6015-17
148. Le Darz A, Mingot A, Bouazza F, et al. Fluorinated pyrrolidines and piperidines containing tertiary benzenesulfonamides: selective carbonic anhydrase II inhibitors. J Enzyme Inhib Med Chem 2015; 30: 737-45
149. DAscenzio M, Carradori SD, Monte C, et al. Design, synthesis and evaluation of N-substituted saccharin derivatives as selective inhibitors of tumor-associated carbonic anhydrase XII. Bioorg Med Chem 2014; 22: 1821-31
150. De Monte C, Carradori S, Secci D, et al. Cyclic tertiary sulfamates: selective inhibition of the tumor-associated carbonic anhydrases IX and XII by N-and O-substituted acesulfame derivatives. Eur J Med Chem 2014; 84: 240-6
151. DAscenzio M, Carradori S, Secci D, et al. Selective inhibition of human carbonic anhydrases by novel amide derivatives of probenecid: synthesis, biological evaluation and molecular modelling studies. Bioorg Med Chem 2014; 22: 3982-8
152. Carradori S, Mollica A, Ceruso M, et al. New amide derivatives of probenecid as selective inhibitors of carbonic anhydrase IX and XII: biological evaluation and molecular modelling studies. Bioorg Med Chem 2015; 23: 2975-81
153. Mollica A, Costante R, Akdemir A, et al. Exploring new probenecid-based carbonic anhydrase inhibitors: synthesis, biological evaluation and docking studies. Bioorg Med Chem 2015; 23: 5311-18
154. Gavernet L, Gonzalez Funes JL, Palestro PH, et al. Inhibition pattern of sulfamide-related compounds in binding to carbonic anhydrase isoforms I, II, VII, XII and XIV. Bioorg Med Chem 2013; 21: 1410-18
155. Parkkila S, Innocenti A, Kallio H, et al. The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian α-carbonic anhydrase isoforms. Bioorg Med Chem Lett 2009; 19: 4102-6
156. Innocenti A, Durdagi S, Doostdar N, et al. Nanoscale enzyme inhibitors: fullerenes inhibit carbonic anhydrase by occluding the active site entrance. Bioorg Med Chem 2010; 28:2822
157. Durdagi S, Vullo D, Pan P, et al. Protein-protein interactions: inhibition of mammalian carbonic anhydrases I-XV by the murine inhibitor of carbonic anhydrase and other members of the transferrin family. J Med Chem 2012; 55: 5529-35
158. Banerjee AL, Eiler D, Roy BC, et al. Spacer-based selectivity in the binding of "carbonic anhydrase I" ligands to recombinant human carbonic anhydrase I. Biochemistry 2005; 44: 3211-24
159. Jude KM, Banerjee AL, Haldar MK, et al. Ultrahigh resolution crystal structures of human carbonic anhydrases I and II complexed with "sis of high affinity" inhibitors reveal the molecular basis of high affinity. J Am Chem Soc 2006; 128: 3011-18
160. Vomasta D, Innocenti A, König B, Supuran CT. Carbonic anhydrase inhibitors: two-prong versus mono-prong inhibitors of isoforms I, II, IX, and XII exemplified by photochromic cis-1,2-alpha-dithienylethene derivatives. Bioorg Med Chem Lett 2009; 19: 1283-6
161. Wang ZC, Qin YJ, Wang PF, et al. Sulfonamides containing coumarin moieties selectively and potently inhibit carbonic anhydrases II and IX: design, synthesis, inhibitory activity and 3D-QSAR analysis. Eur J Med Chem 2013; 66: 1-11
162. Wang L, Yang C, Lu W, et al. Discovery of new potent inhibitors for carbonic anhydrase IX by structure-based virtual screening. Bioorg Med Chem Lett 2013; 23: 3496-9
163. Gao R, Liao S, Zhang C, et al. Optimization of heterocyclic substituted benzenesulfonamides as novel carbonic anhydrase IX inhibitors and their structure activity relationship. Eur J Med Chem 2013; 62: 597-604
164. Zhang S, Yang C, Lu W, et al. A highly selective space-folded photo-induced electron transfer fluorescent probe for carbonic anhydrase isozymes IX and its applications for biological imaging. Chem Commun (Camb) 2011; 47: 8301-3
165. Pettersen EO, Ebbesen P, Gieling RG, et al. Targeting tumour hypoxia to prevent cancer metastasis. from biology, biosensing and technology to drug development: the METOXIA consortium. J Enzyme Inhib Med Chem 2015; 30: 689-721
166. Alafeefy AM, Abdel-Aziz HA, Vullo D, et al. Inhibition of human carbonic anhydrase isozymes I, II, IX and XII with a new series of sulfonamides incorporating aroylhydrazone-, [1,2,4]triazolo[3,4-b][1,3,4]thiadiazinyl-or 2-(cyanophenylmethylene)-1,3,4-thiadiazol-3(2H)-yl moieties. J Enzyme Inhib Med Chem 2015; 30: 52-6
167. Winum JY, Supuran CT. Recent advances in the discovery of zinc binding motifs for the development of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2015; 30: 321-4
168. Briganti F, Pierattelli R, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Part 37. Novel classes of carbonic anhydrase inhibitors and their interaction with the native and cobalt-substituted enzyme: kinetic and spectroscopic investigations. Eur J Med Chem 1996; 31: 1001-10
169. Maryanoff BE, Nortey SO, Gardocki JF, et al. Anticonvulsant O-alkyl sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate and related compounds. J Med Chem 1987; 30: 880-7
170. Casini A, Antel J, Abbate F, et al. Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg Med Chem Lett 2003; 13: 841-5
171. Carta F, Di Cesare Mannelli L, Pinard M, et al. A class of sulfonamide carbonic anhydrase inhibitors with neuropathic pain modulating effects. Bioorg Med Chem 2015; 23: 1828-40
172. Bejaoui M, Panatzi E, De Luca V, et al. Acetazolamide protects steatotic liver grafts against cold ischemia reperfusion injury. J Pharmacol Exp Ther 2015; 355: 191-8
173. Di Cesare Mannelli L, Micheli L, Carta F, et al. Carbonic anhydrase inhibition for the management of cerebral ischemia: in vivo evaluation of sulfonamide and coumarin inhibitors. J Enzyme Inhib Med Chem 2016; 31: in press.
174. Palmer C, Supuran CT. A key opinion leader interview: insight into the research and career of Prof. Claudiu T Supuran. Expert Opin Ther Pat 2015; 25: 501-5